BIOCON:NSE-Biocon Limited (INR)

COMMON STOCK | Biotechnology | NSE

Last Closing Price

INR 406.95

Change

0.00 (0.00)%

Market Cap

INR 488.10B

Volume

2.07M

Average Target Price

INR 430.90 (+5.89%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Small Molecules, Biologics, Branded Formulations, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology, and inflammatory diseases. The company provides biosimilars comprising recombinant human insulin, insulin glargine, biosimilar trastuzumab, and other biopharmaceuticals; small molecules, such as active pharmaceutical ingredients and generic formulations; and branded formulation products under the Insugen, Basalog, BIOMAb EGFR, CANMAb, and ALZUMAb brands. It is also involved in the integrated discovery, development, and manufacturing services for small and large molecules, antibody-drug conjugates, and oligonucleotides. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.

Company Website : http://www.biocon.com

Address : 20th KM, Hosur Road, Bengaluru, India, 560100

Employees : 12,609

Fiscal Year End : March

Currency: INR

Country : India

Technical Indicators

Beta : 0.58

52 Week High : 487.75

52 Week Low : 320.70

200 Day Moving Average : 425.81

50 Day Moving Average : 399.83

Shares Held By Insiders : 664.52%

Shares Held by Institutions : 11.16%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SYNGENE:NSE Syngene International Limited

N/A

 INR225.76B 61.90 29.89
DCAL:NSE Dishman Carbogen Amcis Limited

N/A

 INR17.76B 42.71 7.74
PANACEABIO:NSE Panacea Biotec Limited

N/A

 INR16.43B 18.52 28.13
TAKE:NSE TAKE Solutions Limited

N/A

 INR6.95B 4.82 2.79
ZOTA:NSE Zota Health Care Limited

N/A

 INR3.57B 293.35 72.25
SMSLIFE:NSE SMS Lifesciences India Limited

N/A

 INR1.63B 15.41 8.77
LYKALABS:NSE Lyka Labs Limited

N/A

 INR0.76B N/A 7.08
CELESTIAL:NSE Celestial Biolabs Limited

N/A

 INR0.05B 1.09 1.45

ETFs Containing BIOCON

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.62% 75% C 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.62% 75% C 22% F
Trailing 12 Months  
Capital Gain 20.81% 38% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.81% 38% F 15% F
Trailing 5 Years  
Capital Gain 340.46% 100% A+ 95% A
Dividend Return 1.62% 67% D+ 18% F
Total Return 342.09% 100% A+ 94% A
Average Annual (5 Year Horizon)  
Capital Gain 35.25% 100% A+ 90% A-
Dividend Return 0.17% 80% B- 12% F
Total Return 35.42% 100% A+ 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 38.05% 33% F 59% F
Risk Adjusted Return 93.10% 100% A+ 97% A+
Market Capitalization 488.10B 100% A+ 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 79.73 25% F 13% F
Price/Book Ratio 7.15 22% F 13% F
Price / Cash Flow Ratio 38.04 25% F 13% F
EV/EBITDA 30.93 22% F 21% F
Management Effectiveness  
Return on Equity 10.02% 83% B 64% D
Return on Invested Capital 8.25% 89% B+ 62% D-
Return on Assets 4.00% 75% C 65% D
Debt to Equity Ratio 18.23% 43% F 45% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.58 89% B+ 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.